INTRODUCTION
In previous papers the physic?-chemi:al properties and neuromuscular .blockmg actIO? of suxamethonium were revIewed. In thIS article some of the undesirable effects of the drug will be discussed. The ~ction.s on the heart, respiratory system, gastromtestmal tract, eye, central nervous system and uterus are particularly noted and histamine-releasing and placental crossing properties of the drug are mentioned.
THE CARDIOVASCULAR SYSTEM
In their original papers, Taveau (1906, 1911) showed little interest in suxamethonium. They simply stated that the drug resembled the valeryl compound in its action. In curarized rabbits valerycholine produced marked slowing of the heart, and usually,.a ri~e in blood pressure. In very small doses It dId occasionally, however, cause a fall in blood pressure.
. , When suxamethonium was mtroduced mto anaesthetic practice as a muscle relaxant in the early 1950s it was said to have no significant effects on the cardiovascular system in man. Rises in blood pressure had been recorded in experimental animals, but only when very large doses were administered (Bourne et al. 1952 , Thesleff 1952 .
Subsequently, there were many reports of cardiovascular side effects of the drug in man and laboratory animals (Tables 1 and 2). Of these effects profound sinus bradycardia in children was perhaps the most common and alarming. More recently, cardiac arrests due to hyperkalaemia, following the administration of suxamethonium to patients with severe tissue damage or neurological disease, have been reported. Suxamethonium-induced hyperkalaemia will not be discussed in this paper, but will be reviewed at a later stage.
Clinical Features
Suxamethonium produces more profound effects in children than it does in adults. It is generally accepted that over 80 per cent of small children develop changes in cardiac rate or rhythm following a single paralysing intravenous dose of suxamethonium if they are not premedicated with atropine. Sinus bradycardia is most commonly seen, but nodal rhythm and other arrhythmias also occur (Leigh et al. 1957 , Telford and Keats 1957 . Reports of cardiovascular collapse and sev:re cyanosis, despite adequate pulmonary ventIlation, have appeared in the literature, ?ut the author is unaware of any deaths occurnng as. a result of suxamethonium-induced bradycardIa or arrhythmias. Intravenous atropine affords good protection against these effects. Fully digitalized adults react in a similar manner to children, developing rate or rhythm changes following a single dose of the drug (Dowdy and Fabian 1963 ). An increased incidence of ventricular arrhythmias has been observed by some workers but not by others (Perez 1970) . In partially digitalized patients suxamethonium may produce ECG changes identical with those of digitalis toxicity. These actions are tho~ght to be due to the excessive intracellular potassIUm depletion in digitalized hearts due to suxamethonium depolarization.
In normal adults, a single intravenous dose of suxamethonium rarely produces a significant cardiovascular effect. There is frequently a slight hypotension and bradycardia (parasympathetic effect). Subsequent doses of the drug may, however, produce a more profound action (Bullough 1959 , Lupprian and Churchill-Davidson 1960 , Williams et al. 1961 , Mathias et al. 1970 . The most common effect observed in adults is sinus bradycardia, but sinus tachycardia, P-wave changes, nodal rhythm and ventricular arrhythmias have been described. Cardiac standstill for periods of up to 16 seconds has also been recorded (Bullough 1959, Lupprian and Churchill-Davidson 1960) . A second dose of suxamethonium will produce significant changes in cardiac rate or rhythm in 95 per cent of adults provided that the dose exceeds 25 mg and it is injected 2-5 minutes after the preceding dose (Lupprian and Churchill-Davidson 1960, Williams et al. 1961) . A maximum action is usually seen with the second or third injection, but effects have been observed up to the eighth injection, provided that the dose was large enough. The rate of increase of blood levels of suxamethonium appears important in the production of cardiovascular effects. Small intravenous doses are less likely to cause bradycardia or arrhythmias, and these changes are not seen with intramuscular or subcutaneous injections (Glouachi et al. 1958 .
Although suxamethonium may be thought of as an arrhythmogenic drug, it has also been used as an anti-arrhythmic. Galindo et al. (1972) report that junctional (nodal) rhythm occurring during halothane anaesthesia can be readily reverted to sinus rhythm by the injection of 10-20 mg of suxamethonium intravenously .
.110de oj Action
The possible local and general actions of suxamethonium on the circulation are summarized in Figure 1 .
Suxamethonium is thought to act at cholinergic sites in the autonomic nervous system either by direct action or by inhibition of acetvlcholinesterase which would allow accumul~tion of acetylcholine at these sites.
The initial slight bradycardia and hypotension seen with a single dose of the drug is thought to be a manifestation of its muscarinic effect (parasympathetic stimulation) and can be abolished by atropine. This lasts for about half a minute and superseded by a mild tachycardia and hypertension lasting about a minute. This is a nicotinic effect (sympathetic stimulation) which can be abolished by hexamethonium, trimetaphan or other ganglion-blocking agents. It has been postulated that the parasympathetic effects occur first because the parasympathetic nerve endings are more permeable than the sympathetic endings (Adriani 1964) . A second dose of suxamethonium given within two minutes of the first will not produce change in cardiac rate or rhythm. It is thought that this is due to the protection afforded by the nicotinic effects of the drug. The reason for the profound effect of suxamethonium in children and on repeated injection in adults is unknown but acetyl -cholinesterase inhibition has been postulated (Beretervide 1955). Besides acting on the efferent pathways of the cardiac reflexes, suxamethonium has recently been shown to stimulate afferents in the carotid sinus (:IIathias et al. 1970) . Injection of the drug into the common carotid artery produces an immediate bradycardia. This effect can be abolished by pretreatment with d-tubocurarine or alcuronium. It is said that this is a block of the afferent pathways because the valsalva reflex remains intact and because an efferent block by d -tubocurarine would cause a tachycardia.
Finally, there is evidence that suxamethonium may act on cholinergic receptors Anaesthesia and Intensive Care, Vol. 11, No. 1, February, 1974 in the heart or directly on the myocardium itself. Goat (1972) demonstrated a biphasic action of the drug in isolated rabbit hearts. At low concentrations a negative chronotropic action is produced and at high concentrations there is a positive chronotropic action. Lowered cardiac excitability threshold, predisposition to severe ventricular arrhythmias and reduced myocardial contractility have also been recorded in monkeys subjected to prolonged suxamethonium infusion (Galindo and Davis 1962) . The unusual effect of the drug in a digitalized patient is also presented as evidence of a direct myocardial depolarization (Dowdy and Fabian 1963) .
Prevention of Arrhythmias
Intravenous injection of atropine in a dose of 10 p.gjkg provides adequate protection against suxamethonium -induced vagal arrhythmias (Lupprian and Churchill-Davidson 1960 , Adriani 1964 . Intramuscular atropinization does not provide as effective prophylaxis. The addition of atropine to suxamethonium prior to injection is advocated by many clinicians, particularly those concerned with paediatric anaesthesia. The arrhythmogenic action of suxamethonium is greatly reduced when it is given by the intramuscular or subcutaneous route (Glouachi et al. 1958 , and the addition of atropine to the solution appears unnecessary in these circumstances.
Suxamethonium-induced arrhythmias can also be prevented or abolished by ganglion blocking agents (Adriani 1964 , Mathias et al. 1970 ) and non-depolarizing relaxants (Mathias et al. 1970) . Deep anaesthesia is also said to afford some protection against arrhythmias .
Circulation Time
It is well established that suxamethonium is capable of producing considerable effects on the circulation. Conversely, the circulation may significantly effect the action of suxamethonium. Harrison (1966) demonstrated that, in patients with low cardiac outputs, the incidence of muscle fasciculation was low, and laryngeal relaxation was frequently inadequate when normal doses of the drug were administered. He related this to slow circulation time and increased hydrolysis due to longer exposure to cholinesterase.
More recently Harrison and Junius (1972) demonstrated a significant correlation between circulation time and the development of maximal neuromuscular block.
The latter was delayed up to 2t minutes in some patients with severe cardiac disease. They also noted that fasciculations were delayed and reduced (or absent), but were unable to demonstrate any marked alteration in the duration of action of the drug. In nearly all cases intubating conditions were satisfactory with doses of 1 mgjkg of suxamethonium provided sufficient time was allowed for the maximal block to develop.
THE RESPIRATORY SYSTEM
By far the most profound effect of suxamethonium on the respiratory system is the production of apnoea due to paralysis of the diaphragm and intercostal muscles. The dose which is required to arrest respiration is approximately two to three times that required to immobilize a subject by paralysis of the peripheral musculature (Thesleff 1952) .
The effect of suxamethonium on mucous secretion in the respiratory tract is uncertain. Bovet et al. (1949) reported increased secretion in dogs following an injection of the drug. This was not confirmed in man by other authors (Bourne et al. 1952 ) even when large doses were administered. It was noted, however, that the insertion of instruments into the mouths of lightly anaesthetized, unatropinized patients produced hypersecretion of mucus in the pharynx and respiratory tract.
Nonetheless, several authors state that suxamethonium does produce excessive secretions (Crawford 1962, Wood-Smith, Stewart and Vickers 1968) and the manufacturers include "excessive salivation" in their list of adverse reactions to the drug (Burroughs Wellcome).
Bronchospasm following the administration of suxamethonium has been well documented, but it occurs very rarely and usually in a small group of susceptible individuals. This is usually a histamine release effect occurring in patients with an allergic diathesis (see elsewhere in this article). Occasionally, however, there is no evidence of an allergic response. Eustace (1967) reports marked bronchospasm following suxamethonium administration to two bronchitic patients. Subsequent skin tests were negative.
THE GASTRO-INTESTINAL TRACT-INTRAGASTRIC PRESSURE
Several authors have investigated the effect of suxamethonium administration on intragastric pressure, and the majority have recorded a rise in tension (Roe 1962 , Andersen 1962 , Spence, Moir and Finlay 1967 , La Cour 1969 Miller and Way 1971 , Salem, Wong and Lin 1972 . Their findings are summarized in Tables  3 and 4 . Most workers used an intragastric balloon as a pressure-sensing device, but Spence et al. (1967) employed only a simple gastric tube in their studies. The failure of the latter authors to record significant pressure changes has been attributed to their use of such a tube and to the administration of deep halothane anaesthesia prior to the injection of the suxamethonium (La Cour 1969) . The highest pressures were recorded during the fasciculations, and following these there was often a fall in tension to below the resting level. As suxamethonium has little action on the smooth muscle of the gastro-intestinal tract (Thesleff 1952 ), it appears that the rise in pressure is entirely due to an increase in intraabdominal tension which is related to the intensity of the fasciculations. No significant increase in intragastric pressure was recorded in infants and children (Salem, Wong and Lin 1972) and this is consistent with the low incidence of strong fasciculations in this group (Table 4) .
La Cour (1969) was unable to demonstrate any differences in the development of intragastric pressure between males and females, or where different doses of suxamethonium were administered (40-60 mg/m 2 range).
The physiology of the gastro-oesophageal junction was described by l\Iarchand (1955), and using cadavers he showed that this " sphincter" was competent for intragastric pressures up to 28 cm H 2 0. Clark and Riddock (1962) showed that 20 cm H 2 0 was a more realistic value in the living patient. However, when the normal oblique entry of the oesophagus into the stomach is altered by pregnancy, ascites, bowel obstruction, obesity or hiatus hernia the competence of the gastro-oesophageal junction is frequently less than 15 cm H 2 0 (O' Mullane 1954 , Marchandl955, 1957 , Greenan 1961 , Miller and Way 1971 (Table 5 ). As intragastric pressures of up to 85 cm H 2 0 have been recorded following the injection of suxamethonium, it is apparent that the drug should be used with great care in the emergency situation (La Cour 1969) . Furthermore, suxamethonium increases the risk of inhalation by paralysing the cricopharyngeus and laryngeal musculature (Snow 1963 , Denison Davies 1963 .
The use of the 40° head-up tilt position, which will prevent inhalation at pressures up to 18 cm H 2 0 (Morton and Wylie 1951 , Snow and Nunn 1959 , Hodges, Tunstall and Bennett 1960 , is quite inadequate to handle the large increases in intragastric tension which may follow an injection of suxamethonium. On the other hand, the application of cricoid pressure (Sellick 1961 , Fanning 1970 effectively prevents inhalation provided that active vomiting does not occur. Forcible ejection of gastric contents can be prevented by ensuring complete muscular relaxation (Wylie 1963). The cricoid pressure technique is enhanced by leaving a plastic (nonocclusive) nasogastric tube in situ to act as a " blow-off" valve (Sellick 1962, Salem, Wong and Fizzotti 1972) .
Various drugs have been used to reduce the risk of regurgitation when suxamethonium is used in emergency anaesthesia. Greenan (1961) observed that the intragastric pressure increased "~}laesthl'sia ami Iuinlsive Carc, Vol. II, Xo. ], February, 1974 when the vagus was stimulated, and others reported a considerable increase in gastrooesophageal competence following vagotomy (Table 5 ). This is why adequate preoperative atropinization of patients at risk has been advocated by some authors (Clark and Riddock 1962, Snow 1963) . Miller and Way (1971) , on the other hand, were unable to demonstrate any reduction in intragastric pressure rise following atropine. An effective reduction in rise can be demonstrated, however, when the administration of suxamethonium is preceded by a non-depolarizing agent or lignocaine ( (Cullen 1971) . The use of lignocaine is not recommended because an effective dose is likely to produce toxic reactions. While studying the actions of muscle relaxants at the University of Graz in 1953, Hofmann and Holzer reported that suxamethonium raised the intraocular pressure in conscious subjects by up to 18 mm Hg. They stated that this increased pressure probably resulted from contraction of the extra ocular muscles. Subsequently Lincoff and his colleagues (1955) prefaced a paper on the subject with the statement: "Although no accidents have been reported, the results of the work to be described herein indicate that, because of the peculiar property of the drug which results in a rise in intraocular pressure, succinylcholine should not be used in intraocular surgery". Other authors (Taylor, Mulcahy and Nightingale 1968 ) state that they have used the drug in ophthalmic surgery for many years without serious corn plica tions.
The main points of controversy in this matter are the methods used for measuring intraocular pressure, the aetiology of the rise in tension, the assessment of which patients are at risk, and possible methods of reducing the rise in tension following the administration of suxamethonium.
The most important factor determining the internal pressure of the eye is the aqueous humour, the hydrostatic pressure of the blood accounting for only one-quarter of the total resting intraocular tension (Carballo 1965) . The aqueous, which is formed by the ciliary process under the influence of carbonic anhydrase passes into the posterior chamber, through the pupil into the anterior chamber, and leaves the eye by way of the canal of Schlemm (Figure 2 ). Rapid increases in intraocular tension are usually due to increased aqueous production and compensation for rises in pressure is usually accomplished by increased outflow of the aqueous. Table 7 indicates the levels of intraocular pressure which occur in physiological and pathological states.
The internal tension of the eye can be measured by two methods: manometry and tonometry. Manometry involves cannulation of the anterior chamber of the eye. The cannula is usually attached to a transducerpen-recorder system. This method gives a direct, continuous recording but because of the invasive nature of the monitoring it has only been used in animal experiments, and is considered unsuitable for use in man (Lincoff , Dillon et al. 1957b , Wretland and Wahlin 1958 , Carballo 1965 , Adams and Barnett 1966 . Tonometry must be considered an inferior form of measurement to manometry. Not only is it an indirect method, but also it does not permit continuous monitoring, so that the major peaks in pressure may be missed (Adams and Barnett 1966, Taylor et al. 1968) . Two main types of tonometry are available: applanation and indentation.
Applanation tonometry is more accurate and is based on the principle that when a plane surface is applied to the eye the flattened area produced is inversely proportional to the intraocular pressure. Unfortunately, this method can only be used in patients in the upright position and is unsuitable for anaesthetized subjects. Indentation tonometry using a Schiotz tonometer and a Freidenwald nomogram (Adler 1965 ) is the most commonly used but least accurate method of assessing intraocular pressure (Schwartz and de Roetth 1958 , Adams and Barnett 1966 , Taylor et al. 1968 .
Following an injection of suxamethonium, the intraocular pressure usually reaches a maximum within 20 seconds. The tension rarely rises more than 20 mm Hg above the resting level, and frequently falls to below the resting value within 2-5 minutes ( Table 8 ). The mechanism of these pressure changes is only partially understood. Variations in muscle tension, haemodynamic changes, and variations in aqueous production and drainage have all been implicated.
It was originally thought that contraction of the extraocular muscles was responsible for the raised pressure (Hofmann and Holzer 1953 , Lincoff et al. 1955 , Dillon et al. 1957 a, 1957b , Schwartz and de Roetth 1958 . These muscles are highly specialized and are unlike striated muscles found elsewhere in the body (Lincoff et al. 1955 , Carballo 1965 , Eakins and Katz 1966 , Katz, Eakins and Lord 1968 . They contain two separate neuromuscular systems. The first is a "twitch" system similar to the normal skeletal neuromuscular arrangement seen in mammals. The second is a "tonic" neuromuscular system which is similar to that found in amphibians and birds. The type of muscle fibre involved here cannot be stimulated by a single twitch but requires a tetanic stimulus to produce contraction. The administration of suxamethonium in doses which abolish the twitch response in normal striated muscle may produce a marked increase in the baseline tension of the extraocular muscles without a significant fall-off in its twitch response. The clinical importance of this action is that suxamethonium-induced responses of the muscle may lead to an increase in intraocular tension or difficulties in estimating resting muscle lengths during squint operations.
Several authors have presented evidence to support their claims that extraocular muscle contraction is the main cause of the suxamethonium-induced rise in intraocular tension. Abolition of this rise has been reported following sectioning of all the extraocular muscles, or following the paralysis of these muscles produced by a nondepolarizing agent (Katz et al. 1968 ). These results, however, are not universally accepted and some authors report that a rise in intraocular pressure cannot be prevented by paralysing the eye muscles with d-tubocurarine (Wretlind and Wahlin 1959) . The role of the orbital smooth muscle is even more uncertain. Difficulty arises not only from the technical problem involved in the measurement of contraction and retraction of the smooth muscle, but also from the fact that extraocular muscle is capable of an adrenergic response (Katz and Eakin 1966) . Wretlind and Wahlin (1959) reported that the smooth muscle of the orbit was relaxed during the period of maximal intraocular tension.
Haemodynamic changes within the orbit have also been proposed as the cause of raised intraocular pressure. Although variations in arterial blood pressure and central venous pressure have little effect on the eye, changes in the ocular vessels appear to be of considerable importance (Dillon et al. 1957b , Sobel 1962 , Adams and Barnett 1966 . Hallidin et al. (1959) were able to produce photographic evidence of transient vasodilatation of the conjunctiva following suxamethonium injection.
They demonstrated a mean increase in the diameter of conjunctival vessels of 38 per cent in nine patients following 50-100 mg of suxamethonium. Adams and Barnett (1966) postulated the vasodilatation of the choroidal blood vessels was responsible for the rise in intraocular tension and were able to show that an injection of bradykinin, a potent vasodilator, into the carotid artery produced a very similar effect to suxamethonium.
Evidence has also been presented that suxamethonium action on the eye may be a secretory phenomenon. Carballo (1965) was able to prevent rises in intraocular tension by pretreating patients with acetazolamide. This reduces aqueous formation by inhibiting carbonic anhydrase in the ciliary body ( Figure 2 ).
There is a wide diversity of opinion concerning the use of suxamethonium in eye surgery. Some authors feel that it is never indicated, others that it is rarely contra-indicated. Two facts are well established. One is that suxamethonium raises intraocular pressure, the other is that this pressure falls to normal or subnormal levels within five minutes, even when the suxamethonium administration is continued. The drug should therefore not be given for the first time during an operation in which the eye has been opened, and it is best avoided in cases of open eye injury. It is also not recommended on theoretical grounds in patients with closed-angle glaucoma (Lincoff et al. 1955 , Dillon et al. 1957a , Schwartz and de Roetth 1958 , Taylor et al. 1968 ). The drug, however, can be used for open operations (cataract, corneal graft) provided the incision is not made within five minutes of the injection. It also appears safe in open-angle (wide-angle, simple) glaucoma (Schwartz and de Roetth 1958 , Adams and Barnett 1966 , Taylor et al. 1968 ). Some ophthalmic surgeons maintain that suxamethonium is unsuitable for squint operations because of the artificial shortening of the muscle which may be produced by prolonged contraction.
Several methods have been suggested to avoid the rise in intraocular tension which accompanies the administration of suxamethonium. The most practical is the injection of a small dose of non-depolarizing agent (d-tubocurarine 3-5 mg, gallamine 20 mg) about three minutes prior to the use of suxamethonium (Miller, Way and Bickey 1968) . Table 9 indicates that in normal The Rise in Intra-ocular Pressure which Follows Suxamethonium Administration is Effectively Reduced by Pretreatment with aNon-depolarizing Agent (Miller, Way and Hickey, 1968) DRUGS and glaucomatous patients a rise of tension can largely be avoided by such pretreatment. Another suggested method is the injection of 500 mg of acetazolamide two to three minutes prior to the suxamethonium (Carballo 1965, Table 10 ). Bexafluorenium has also been used successfully to reduce the suxamethoniuminduced rise in intraocular tension (Katz et al. 1968 , Table 11 ). The time interval between the injection of hexafluorenium and suxamethonium appears crucial. Sobel (1962) was unable to demonstrate any protective action in his series, and it is suggested that this was because the time interval was greater than five minutes. The mechanism of the protective action of hexafluorenium is poorly understood. It is unlikely to be due to its anticholinesterase effect as neostigmine and edrophonium increase the action of suxamethonium on the eye. It is possible that the effect of hexafluorenium is due to its activity on the junctional membrane or its non-depolarizing action. Attempts have been made to reduce the ocular effects of suxamethonium by administering it as an infusion, or by intermittent injection, but this has not proved effective (Schwartz and de Roetth 1958 , Katz et al. 1968 . The anaesthetist is occasionally confronted with a patient with a full stomach presenting for surgery for an open eye injury. \Vhether suxamethonium is used or not must be decided by the individual. If it is used, however, two things should be kept in mind. First, excessive rise in intraocular tension can be prevented by a prior injection of a non-depolarizer, and second, a larger dose of suxamethonium (1·5 mg/kg) will be required after such pretreatment (Cullen 1971) .
THE CENTRAL NERVOUS SYSTEM
In the normal clinical situation suxamethonium has no direct effect on the brain or spinal cord. In large doses the drug has been shown to depress the respiratory centre in cats (Ellis, Norton and l\Iorgan 1952) .
Despite the apparent central inactivity of the drug, there is good reason to suspect that it is capable of profound cerebral effects and that its failure to produce these effects is due to its inability to cross the "blood-brain barrier" in sufficient concentration.
Two related quaternary amines, acetylcholine and d-tubocurarine, have no action on the central nervous system when administered intravenously but produce marked stimulation when injected into the cerebral ventricles (Chang 1953 , Michenfelder 1969 , Goldstein et al. 1969 . Acetylcholine produces a curious catatonic stupor and d-tubocurarine produces tremor, myoclonic contractions, crying out, and generalized convulsions.
The failure of suxamethonium to cross the "blood-brain barrier" in significant amounts is due largely to two factors: its low lipid/water partition coefficient and the ionized state of the molecule. Lipid insoluble substances cross only slowly into the brain and they are rapidly removed by cerebrospinal fluid flow so that their cerebral concentrations remain low, Ionized substances also pass slowly into the brain. This is particularly so if they are positively charged like suxamethonium because there is a blood cerebrospinal fluid potential gradient of about 3-10 mV at pH 7·4 (cerebrospinal fluid positive) which opposes the passage of such charged molecules (Goldstein et al. 1969 , Rall 1971 .
Suxamethonium has been shown to raise the cerebrospinal fluid pressure (Halldin and Wahlin 1959) . Fifteen anaesthetized patients hyperventilated to prevent carbon dioxide retention exhibited a rise of between 5 mm and 320 mm H 2 0 above the initial value. This rise commenced within one minute of the injection of the drug and persisted throughout the period of apnoea. After this the pressure fell to a minimum about seven minutes after the injection (average of 10·4 mm H 2 0 below the resting value). It was postUlated that these pressure changes were due to alteration in cerebral blood flow caused by the suxamethonium. Raised intracranial pressure with subsequent medullary coning has been suggested as a possible cause of prolonged apnoea following the administration of suxamethonium to patients with spaceoccupying lesions (Filis and J0rgensen 1961) .
Finally, the action of suxamethonium may be significantly altered in the presence of neuropathological states such as paraplegia, hemiplegia, multiple sclerosis and tetanus. The development of hyperkalaemia in these . and similar conditions will be the subject of a future paper.
THE PLACENTA
The possibility of placental transmission of suxamethonium was first investigated by Thesleff in 1952 . Following the administration of large doses of the drug to full-term pregnant rabbits, he was unable to demonstrate muscle weakness in the offspring. Similarly, no flaccidity was observed in the foetuses of three women who had their pregnancies terminated during the fifth month.
Spastic paralysis in puppies, lasting three to five minutes, has, however, been demonstrated following the injection of large doses of suxamethonium into the uterine artery of the mother immediately prior to delivery (Pittinger and Morris 1955) .
Subsequently, a large number of authors (reviewed by Moya and Kvisselgaard 1961) expressed opinions on the advisability of using suxamethonium during operative delivery. These opinions were based on the clinical appearance of the neon ate following delivery. Most authors felt that there was no significant flaccidity present at birth.
No attempts were made to measure neonatal levels of suxamethonium until 1961. Moya and Kvisselgaard used a method described by Norton and de Beer (1954) and subsequently altered by them (Kvisselgaard and Moya 1961a) . Schermund et al. (1961) used a similar method. Both were based on the contracture of frog rectus abdominus muscle. Concentrations down to 0'1-1·0 fLgfml of serum can be measured by this method. Blood samples were taken at delivery from the mother and the neonate, and anticholinesterase was added to prevent hydrolysis of the suxamethonium. With 100 mg doses, no placental transmission of the drug could be demonstrated. However, with doses of 300-500 mg small but detectable quantities of suxamethonium were found in the umbilical vein blood, although none of the neonates appeared affected by the drug (K visselgaard and Moya 1961b) . In studies with rabbits, doses of 1,000 times the normal paralysing dose were required to produce flaccid foetuses.
As far as the author is aware, there have been no attempts to measure blood levels of suxamethonium in the foetus by physico-chemical methods.
Thin layer chromatography and infra-red spectrophotometry may possibly present a less tedious method of analysis.
The factors concerned in placental transmission of drugs are similar to those concerned in the transfer of drugs across the blood brain barrier. Transmission is facilitated by high concentration, low molecular weight, and lipid solubility. It is opposed by plasma protein binding of the drug, ionization and low lipid/water partition coefficient (Goldstein et al. 1969 , Long and Marks 1969 , Asling and Way 1971 . Water-soluble quaternary bases with high pKa's, like d-tubocurarine and suxamethonium, usually show negligible placental transfer.
Cholinesterase is known to be present in large quantities in placental tissue Margolies 1961, Goldstein et al. 1969) , and it has been suggested that suxamethonium hydrolysis by the placenta might explain the low permeability of the drug. Incubation of suxamethonium with placental homogenates, however, produces little breakdown and it appears that the enzyme present is almost exclusively the specific acetylcholinesterase (Moya and Margolies 1961) .
In regard to the use of suxamethonium in pregnancy, Burroughs Wellcome Company states: "The safe use of succinylcholine has not been established with respect to possible adverse effects upon foetal development. Therefore, it should not be used in women of child-bearing potential and particularly during early pregnancy unless, in the judgement of the physician, the potential benefits outweigh the unknown hazards."
THE UTERUS
Conflicting views have been expressed concerning the action of suxamethonium on the uterus. On the one hand it has been recommended as a useful drug for relaxing the uterus in obstetric emergencies (Alver et al. 1962) , while on the other it has been condemned on the grounds that it produces uterine spasm and endangers the placental blood supply (Felton and Goddard 1966) . Table 12 summarizes the results of several authors who have studied this subject.
There are reasons why alteration in uterine activity under the influence of the drug might be suspected. The uterus is supplied with cholinergic fibres and acetylcholine stimulates uterine contraction (Alver et al. 1962 , Reier and Moster 1970 , Nakanishi and Wood 1971 . It would appear, however, that although the human non-pregnant myometrium possesses sensitive cholinergic muscarinic receptors these are markedly suppressed during pregnancy when the uterus is mainly under sex hormone control.
The methods and the findings of the various authors require some comment (Table 12) . The uterus has been studied under a variety of conditions: non-pregnant, pregnant; at term, not at term; in labour, and not in labour; in vitro and in vivo. Different species have been used in the studies and different methods of measuring uterine contraction have been employed.
In no case has a fall in intra-uterine pressure been demonstrated. Alver et al. (1962) recorded only a clinical impression and did not use a pressure-measuring device. Furthermore, only in the study of Felton and Goddard (1966) has there been a measured rise in pressure. This was a series of only five patients in which a rise of one and a half to two times the resting pressure was recorded. It would, however, seem surprising that other workers have not recorded similar rises because the uterus, being intra-abdominal like the stomach, might be expected to undergo similar pressure changes during suxamethonium fasciculations (Healy 1971) .
Most authors recorded no change in the intrauterine pressure in vivo following an injection of suxamethonium (Wiqvist and Wahlin 1962 , Healy 1971 , Iuppa et al. 1971 . A byphasic action of the drug has however been reported in vitro using strips of human myometrium (Iuppa et al. 1971) . In low concentrations the activity was increased, and at high concentrations it was decreased. These results are not in agreement with those of Reier and Moster (1970) , who were unable to demonstrate any change in the activity of myometrial strips under similar experimental conditions.
Although the controversy remains unresolved, it would seem reasonable to comment that, in the clinical situation, it appears unlikely that suxamethonium has any significant, useful or harmful effect on the pregnant human uterus.
HISTAMINE RELEASE
Von Dardel and Thesleff (1952) were unable to demonstrate any histamine releasing properties of suxamethonium. Bourne et al. (1952) , however, reported that it has about one-hundredth the activity of d-tubocurarine in this regard. Paton (1959) agreed with this, stating that all muscle relaxants which he had tested exhibited some action of this nature. However, he felt that no significant effect would be produced by suxamethonium doses less than 5 mg/kg. He did, however, postulate that under certain circumstances levels of histamine capable of producing clinical manifestations could be produced. First, this could occur in patients who were predisposed to " allergic-type" reactions. Second, this might occur when large total doses of suxamethonium were given by intermittent injection or intravenous infusion. Under these circumstances there could be a build-up of succinylmonocholine due to its slower rate of hydrolysis. Although the neuromuscular blocking action of this substance is much less than that of suxamethonium, its histamine-release properties are similar and this could account for an " allergic" reaction. There are a number of cases in the literature supporting the claim that suxamethonium is capable of evoking such responses (Table 13 ). Smith (1957) reported four cases, three with urticarial reactions and one (an asthmatic) with bronchospasm. He also tested over 50 individuals and showed that they.all have some degree of skin response to intradermal suxamethonium.
Other writers have reported reactions including severe wheals, bronchospasm, hypotension, bradycardia and .. anaphylaxis". Kepes and Haimovici (1959) reported a severe urticarial skin rash accompanied by bradycardia and hypotension which occurred in one individual on three occasions with intravenous suxamethonium. No reaction was seen with intradermal testing. Several authors have reported severe bronchospasm (Smith 1957 , Fellini, Bernstein and Zauder 1963 , Bele-Binda and Valeri 1971 , Katz and Mulligan 1972 . In the majority of these patients there was no preceding history of asthma, although half had previously experienced allergic reactions of some kind. Most of these patients had strongly positive skin reactions which could be modified by prior administration of antihistamines. Jerums, Whittingham and Wilson (1967) reported an "anaphylactic-type" response in a 26-year-old woman on two occasions which led to cardio-respiratory collapse and skin rashes.
Positive immediate reagin-type cutaneous hypersensitivity and Prausnitz-Kuster reactions were given as evidence that this was in fact an anaphylactic response.
These cases illustrate that although histamine release reactions are rare, with suxamethonium they are by no means unknown, and may be sufficiently severe to threaten life.
